• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nuvalent Inc. filed SEC Form 8-K: Leadership Update

    6/10/25 4:37:05 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVL alert in real time by email
    8-K
    false000186156000018615602025-06-092025-06-09

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 9, 2025

    NUVALENT, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    001-40671

    81-5112298

    (State or other jurisdiction
    of incorporation)

    (Commission
    File Number)

    (I.R.S. Employer
    Identification No.)

    Nuvalent, Inc.

    One Broadway, 14th Floor, Cambridge, Massachusetts 02142

    (Address of principal executive offices, including zip code)

    (857) 357-7000

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trade
    Symbol(s)

    Name of each exchange
    on which registered

    Class A Common Stock, $0.0001 par value per share

    NUVL

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 9, 2025, Emily Conley, a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of her decision to resign from the Board and from all committees of the Board on which she serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders. Ms. Conley’s decision to resign was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

     

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Nuvalent, Inc.

     

     

     

    Date: June 10, 2025

    By:

    /s/ Deborah A. Miller

     

     

    Deborah A. Miller, Ph.D.

     

     

    Chief Legal Officer and Secretary

     


    Get the next $NUVL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUVL

    DatePrice TargetRatingAnalyst
    3/14/2025$100.00Neutral → Buy
    UBS
    12/30/2024$110.00Buy
    H.C. Wainwright
    10/24/2024$100.00Neutral
    UBS
    8/29/2024$100.00Overweight
    Barclays
    4/17/2024$97.00Buy
    Jefferies
    4/1/2024$69.00 → $110.00Market Perform → Outperform
    Leerink Partners
    2/28/2024$99.00Buy
    Guggenheim
    2/23/2024$105.00Outperform
    Robert W. Baird
    More analyst ratings

    $NUVL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

      Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission by mid-year 2025 Initiation of ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC planned for first half of 2025 Pivotal data for neladalkib in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Strengthened leadership team with key internal promotions CAMBRIDGE, Mass., May 8, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in ca

      5/8/25 7:31:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, which supports the rational molecular design of zidesamtinib, its novel and selective ROS1 inhibitor. Zidesamtinib is currently being evaluated in the ongoing ARROS-1 Phase 1/2 trial for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors, which is designed with registrational intent for tyrosine

      4/29/25 1:09:00 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

      CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced two "Trial in Progress" poster presentations for its novel ALK-selective inhibitor, neladalkib, and novel HER2-selective inhibitor, NVL-330, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 – June 5, 2025, in Chicago. Posters will be archived on the Nuvalent website at www.nuvalent.com. The first "Trial in Progr

      4/23/25 10:28:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nuvalent upgraded by UBS with a new price target

      UBS upgraded Nuvalent from Neutral to Buy and set a new price target of $100.00

      3/14/25 7:39:21 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Nuvalent with a new price target

      H.C. Wainwright initiated coverage of Nuvalent with a rating of Buy and set a new price target of $110.00

      12/30/24 7:15:09 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Nuvalent with a new price target

      UBS initiated coverage of Nuvalent with a rating of Neutral and set a new price target of $100.00

      10/24/24 6:26:48 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Pelish Henry E. exercised 200 shares at a strike of $28.59 and sold $15,964 worth of shares (200 units at $79.82) (SEC Form 4)

      4 - Nuvalent, Inc. (0001861560) (Issuer)

      6/10/25 4:38:09 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Noci Darlene exercised 4,000 shares at a strike of $20.69 and sold $285,236 worth of shares (4,000 units at $71.31) (SEC Form 4)

      4 - Nuvalent, Inc. (0001861560) (Issuer)

      5/30/25 4:31:26 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Porter James Richard exercised 27,000 shares at a strike of $27.85 and sold $1,879,216 worth of shares (27,000 units at $69.60) (SEC Form 4)

      4 - Nuvalent, Inc. (0001861560) (Issuer)

      5/16/25 4:30:25 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVL
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuvalent Appoints Grant Bogle to Board of Directors

      CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant Bogle to its Board of Directors. "Grant's demonstrated success in leading the growth and evolution of oncology biotechnology companies augments our Board as we work towards a potential first approval from our pipeline of novel kinase inhibitors in 2026," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We wel

      12/9/24 6:30:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

      CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors. An experienced drug developer and medical oncologist who has contributed to the successful development and commercialization of multiple new therapies for patients with cancer, Dr. Meyers has served as a Senior Clinical Advisor to Nuvalent since 2020. "We look forward to

      10/6/22 6:30:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvalent Appoints Anna Protopapas as Chair of Board of Directors

      Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, as Chair of its Board of Directors. "I am excited to join the Nuvalent Board of Directors and have been impressed

      3/31/22 6:30:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

      SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

      11/14/24 4:50:28 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

      SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

      11/14/24 4:34:36 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvalent Inc. (Amendment)

      SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

      5/15/24 6:39:30 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVL
    Financials

    Live finance-specific insights

    See more
    • Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

      Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase 3 randomized, controlled trial of NVL-655 for treatment-naïve patients with advanced ALK-positive NSCLC anticipated in the first half of 2025 Company to host a conference call today at 8:30 a.m. ET/2:30 p.m. CEST CAMBRIDGE, Mass., Sept. 14, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating pre

      9/14/24 5:00:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

      Updated Phase 1 data from ALKOVE-1 and ARROS-1 clinical trials to be presented at the ESMO Congress 2024 Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment Company plans to host a conference call on September 14, 2024 at 8:30 a.m. ET/2:30 p.m. CEST following oral presentations at ESMO CAMBRIDGE, Mass., Sept. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced data from abstracts to be presented at the European Society for Medical O

      9/9/24 6:30:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

      Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET/2:30 p.m. CEST $658.0 million in cash, cash equivalents and marketable securities expected to support operating runway into 2027 CAMBRIDGE, Mass., Aug. 8, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones, and reported second quarter 2024 financial results.

      8/8/24 6:30:00 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVL
    SEC Filings

    See more
    • Nuvalent Inc. filed SEC Form 8-K: Leadership Update

      8-K - Nuvalent, Inc. (0001861560) (Filer)

      6/10/25 4:37:05 PM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Nuvalent Inc.

      10-Q - Nuvalent, Inc. (0001861560) (Filer)

      5/8/25 7:42:48 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvalent Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Nuvalent, Inc. (0001861560) (Filer)

      5/8/25 7:36:02 AM ET
      $NUVL
      Biotechnology: Pharmaceutical Preparations
      Health Care